Free Trial
NASDAQ:RNXT

RenovoRx Q4 2024 Earnings Report

RenovoRx logo
$1.00 +0.01 (+1.00%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.00 +0.00 (+0.50%)
As of 05/2/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RenovoRx EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

RenovoRx Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.17 million
Beat/Miss
Missed by -$128.00 thousand
YoY Revenue Growth
N/A

RenovoRx Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, April 1, 2025
Conference Call Time
8:30AM ET

Upcoming Earnings

RenovoRx's Q1 2025 earnings is scheduled for Thursday, May 15, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

RenovoRx Earnings Headlines

RenovoRx (RNXT) Projected to Post Earnings on Friday
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
See More RenovoRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email.

About RenovoRx

RenovoRx (NASDAQ:RNXT), a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

View RenovoRx Profile

More Earnings Resources from MarketBeat